UK biotech sees boost in biotech fundraising so far this year; ChemoCentryx kills plans for stock offer
→ BIA and Informa Pharma Intelligence reported Friday that the UK biotech industry saw $2.05 billion in new fundraising in the first 8 months of this year — more than all of last year. That figure adds venture rounds with IPOs and follow-ons.
→ ChemoCentryx $CCXI is cancelling plans for a new offering to raise cash. The Mountain View, CA-based biotech says that “the company believes that culmination of terms representing the best interests of its stockholders is not to be achieved at the current time.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.